Author:
Hadawale Sakshi,Sharma Sanjay
Reference40 articles.
1. B. Godman, H. McCabe, T. D Leong, D. Mueller, A.P. Martin, I. Hoxha, J.C. Mwita, G.M. Rwegerera, A. Massele, J. de O. Costa, R.C.R.M. do Nascimento, L.L.P. de Lemos, K. Tachkov, P. Milushewa, O. Patrick, L.L. Niba, O. Laius, I. Sefah, S. Abdulsalim, F. Soleymani, A.N. Guantai, L. Achieng, M. Oluka, A. Jakupi, K. Logviss, M.A. Hassali, D. Kibuule, F. Kalemeera, M. Mubita, J. Fadare, O.O. Ogunleye, Z. Saleem, S. Hussain, T. Bochenek, I. Mardare, A.A. Alrasheedy, J. Furst, D. Tomek, V. Markovic-Pekovic, E.M. Rampamba, A. Alfadl, A.A. Amu, Z. Matsebula, T.N.T. Phuong, B.N. Thanh, A. Chichonyi Kalungia, T. Zaranyika, N. Masuka, I.D. Olaru, J. Wale, R. Hill, A. Kurdi, A. Timoney, S. Campbell, J.C. Meyer, Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries, Expert Rev. Pharmacoecon. Outcomes Res. 20 (2020) 1–26. 10.1080/14737167.2020.1734456.
2. Network-based prediction of drug combinations;Cheng;Nat. Commun.,2019
3. Analysis of drug combinations: current methodological landscape;Foucquier;Pharmacol. Res. Perspect.,2015
4. Fixed Dose Combinations Approved by DCG (I) For Year 2022. https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=MTA0NTM=, 2022 (accessed August 9, 2024).
5. Familial hypercholesterolemia: A review;Varghese;Ann. Pediatr. Cardiol.,2014